Result of general meeting

4d pharma plc

("the Company" or" 4d pharma")

Result of general meeting

4d pharma (AIM: DDDD), a pharmaceutical company focusing on significant new therapeutic areas, announces that at the General Meeting held earlier today, all the resolutions put to shareholders were duly passed.

As a result, the placing announced on 25 June 2014 of 14,333,334 new ordinary shares at 150p per ordinary share to raise £21.5m, is conditional only on Admission which is expected to take place on 14 July 2014.

Following Admission, the Company's issued share capital will consist of 51,582,834 ordinary shares. There are no ordinary shares held in treasury. Therefore, in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company confirms that following Admission, the total number of voting rights in the Company will be 51,582,834.

For Further information please contact:

4d pharma plc

Duncan Peyton

Tel: 0161 837 6200

Zeus Capital Limited (Nominated Adviser and Broker)

Ross Andrews/Dan Bate (Corporate Finance)

Tel: 0161 831 1512

Dominic Wilson (Institutional Sales)

Tel: 020 7533 7727